{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-007217","form_type":"8-K","ticker":"BYSI","cik":"0001677940","company_name":"BeyondSpring Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.125324+00:00","generated_at":"2026-05-16T21:17:51.345001+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BeyondSpring Q3 2025 net loss $1.7M; Plinabulin DCR 85% in NSCLC post-PD-1/L1","bullets":["Net loss from continuing ops $1.7M vs $2.2M YoY; cash $12.5M up from $2.9M Dec 2024.","Plinabulin + docetaxel + Keytruda in NSCLC: DCR 85%, median PFS 7.0 mo, 12-mo OS 79%.","SEED (38% owned) closed $30M Series A-3, FDA/NMPA IND clearance for RBM39 degrader.","R&D $1.0M, G&A $0.8M; headcount reductions drove lower admin expenses.","Discontinued ops (SEED sale accounting) net loss $3.2M in Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-007217","json":"https://secwatch.observer/filing/0001171843-25-007217.json","markdown":"https://secwatch.observer/filing/0001171843-25-007217.md","text":"https://secwatch.observer/filing/0001171843-25-007217.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677940/000117184325007217/0001171843-25-007217-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677940/000117184325007217/f8k_111225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:17:51.345001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}